New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 13, 2013
13:23 EDTNEPTNeptune increases equity participation in Acasti Pharma
Neptune Technologies & Bioressources announces it has acquired, through the exercise of a previously issued warrant, 6,750,000 Class A common shares in the capital of Acasti Pharma, a majority-owned subsidiary of Neptune. The shares were acquired at a price of CDN$2.30 per Share upon the exercise of the warrant. This reflects a total exercise price of approximately CDN$15.5M. The warrant was delivered to Neptune pursuant to a royalty prepayment agreement, dated December 4, 2012, entered into between Neptune and Acasti, under which Acasti has exercised the option embedded in its exclusive technology license agreement dated August 7, 2008 entered into between Acasti and Neptune to pay in advance all of the future royalties payable under the License Agreement. As a result of the royalty prepayment transaction, Acasti is no longer required to pay any royalties to Neptune under the License Agreement during its term for the use of the intellectual property under license. The exercise of the warrant has increased Neptune's equity participation in Acasti from approximately 57% to approximately 60% as at July 12.
News For NEPT From The Last 14 Days
Check below for free stories on NEPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 17, 2014
10:11 EDTNEPTNeptune Technologies receives USPTO patent
Reference Link
July 15, 2014
17:56 EDTNEPTNeptune Technologies reports Q1 revenue C$3.64M vs. C$6.08M last year
Gross profit as a percent of revenue was 14% for the current quarter, versus 10% for the corresponding prior year quarter. Reports Q1 Adjusted EBITDA (C$3.77M) vs. (C$2.7M) in the prior year. Reports Q1 net loss (C$5.7M) vs. (C$3.38M) last year.
July 9, 2014
11:24 EDTNEPTHigh option volume stocks
High option volume stocks: GIMO NEPT BPOP AVAV CBSO LL BOBE KWK GNC TCS

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use